Aarti Drugs Share Price Target 2026 — Analyst Forecast, Catalysts and Key Risks

Wed Apr 22 2026

The Aarti Drugs share price target 2026 stands at Rs 517-597 as per analyst consensus — implying 21-40% upside from the current CMP of Rs 427. Investors tracking the Aarti Drugs share price target 2026 need to understand the complete picture — the specific growth catalysts, FY27 earnings timeline, risks, and the bull vs bear case that will determine whether Aarti Drugs (AARTIDRUGS) achieves or misses this 12-month target. This article covers every dimension of the Aarti Drugs share price target 2026 thesis — catalysts, risks, scenarios, analyst ratings, and key levels — updated April 2026.

Click Here — Get Free SEBI-registered Research on Aarti Drugs on Univest.

Table of Contents

Aarti Drugs Share Price Overview — April 2026

Company	Aarti Drugs
NSE Symbol	AARTIDRUGS
Sector	API Generic Pharma / Domestic and Export
CMP April 2026	Rs 427
52-Week High	Rs 657
52-Week Low	Rs 327
Market Cap	Rs 3,660 Cr
Trailing P/E	18x
Dividend FY26	Rs 3
Promoter Holding	50.2%
FII Holding	8.4%
12M Analyst Target	Rs 517-597
Upside from CMP	21-40%

Data from NSE/BSE and publicly available research. April 2026. Verify before investing.

Track live Aarti Drugs price, FII/DII flows and analyst targets on the Univest Screener.

What Is Aarti Drugs?

Get Free Analyst Research on Aarti Drugs — Tap Here.

Aarti Drugs (NSE: AARTIDRUGS) manufactures APIs — metronidazole, tinidazole, ciprofloxacin — for domestic pharma and export. EBITDA margin expanding from 12% to 15%+ as API demand normalises.

Budget 2026-27 Impact on API Generic Pharma

Budget 2026-27’s API PLI and healthcare infrastructure investment support Aarti Drugs’ domestic and export API demand recovery.

Aarti Drugs share price target 2026 — Short, 12-Month and Long-Term Horizons

Horizon	Target	Key Assumption
Short-Term 3-6 Months	Rs 517	Q4 FY26 results beat and technical recovery
12-Month Consensus	Rs 517-597	FY27 earnings delivery and macro normalisation
Long-Term FY27-28	20-30% above 12M	Full earnings recovery and sector re-rating
Bear Case	Rs 327 zone	FY27 miss and extended FII selling

Compare Aarti Drugs with sector peers live on the Univest Screener.

5 Growth Catalysts Supporting the Aarti Drugs share price target 2026

1. India API Generic Pharma Sector — Structural Growth Tailwind

India’s API Generic Pharma sector is expanding at 12-18% annually — driven by rising incomes, urbanisation, government policy, and the India structural growth story. Aarti Drugs’s market position within this sector creates compounding runway that underpins the Aarti Drugs share price target 2026 consensus of Rs 517-597. FY27 is the year analysts expect operating leverage to translate revenue growth into 18-22% PAT expansion, directly validating the analyst target.

2. FY27 Earnings Recovery — Primary Re-Rating Catalyst

After FY26 headwinds from US tariff uncertainty, FII outflows, and sector-specific pressures, analyst consensus projects Aarti Drugs to deliver 15-20% PAT growth in FY27. Q4 FY26 results (April-May 2026) with positive FY27 guidance are the immediate trigger for re-rating toward the Aarti Drugs share price target 2026 consensus of Rs 517-597. Track Q4 results live on the Univest Screener.

3. Competitive Moat — Defensible Market Position Built Over Decades

Aarti Drugs holds a structural competitive moat in its API Generic Pharma segment — brand equity, distribution depth, technical capability, or customer relationships that take 10-15 years to replicate. This moat protects market share during competitive cycles and enables pricing power in upcycles — the structural argument for the premium valuation embedded in the Aarti Drugs share price target 2026 of Rs 517-597.

4. RBI Rate Cut Cycle — Reducing Cost of Capital

India’s RBI rate cut cycle commenced in 2026 reduces Aarti Drugs’s borrowing costs and stimulates end-customer demand for API Generic Pharma products. Lower interest rates improve EBITDA-to-PAT conversion — directly expanding EPS and supporting the Aarti Drugs share price target 2026 of Rs 517-597 by making the earnings multiple more justifiable.

5. Budget 2026-27 Policy Alignment and Government Capex Support

Union Budget 2026-27’s Rs 11.21 lakh crore infrastructure capex, PLI scheme continuity, and consumption incentives create a positive policy backdrop for Aarti Drugs’s API Generic Pharma business. Regulatory clarity and government spending certainty reduce operating risk — improving earnings visibility that directly supports the Aarti Drugs share price target 2026 bull case.

Download the Univest iOS App or Android App for live Aarti Drugs alerts and SEBI-registered research.

5 Risks That Could Impact the Aarti Drugs share price target 2026

1. US Tariff and Global Macro Headwinds

The 26% US reciprocal tariff (April 2026) created FII outflow pressure across Indian equities including Aarti Drugs. Prolonged US-India trade tension would reduce FY27 estimates by 5-10% — the key downside risk to the Aarti Drugs share price target 2026 consensus of Rs 517-597.

2. Valuation at 18x Requires Consistent Execution

At 18x trailing P/E, Aarti Drugs is priced for sustained growth. Any Q4 FY26 miss or FY27 guidance cut triggers multiple compression — the most immediate risk to the Aarti Drugs share price target 2026. The Rs 327 52-week low zone is the key support and stop-loss reference.

3. Competition Intensifying in API Generic Pharma

Domestic and global competitors are investing aggressively in Aarti Drugs’s API Generic Pharma market. Pricing pressure or market share erosion compresses revenue growth visibility and reduces the multiple supporting the Aarti Drugs share price target 2026.

4. Input Cost and Supply Chain Volatility

Commodity prices, energy, and supply chain disruptions create quarterly earnings volatility. Any cost increase that cannot be passed through compresses EBITDA below analyst estimates — creating downside risk to the Aarti Drugs share price target 2026 of Rs 517-597.

5. FII Selling Risk — 8.4% Institutional Holding

With 8.4% FII ownership, Aarti Drugs is exposed to global risk-off events triggering institutional selling disconnected from fundamentals. FII exits temporarily suppress the stock below levels justified by the Aarti Drugs share price target 2026 analyst consensus of Rs 517-597.

Aarti Drugs Bull Case vs Bear Case — Aarti Drugs share price target 2026

Scenario	Price Target	Probability	Trigger
Bull Case	597	Medium	FY27 earnings beat, FII re-entry, sector re-rating
Base Case	Rs 517-597	High	FY27 in-line earnings, stable macro
Bear Case	Rs 327 zone	Low	FY27 guidance cut, prolonged FII selling

Aarti Drugs Share Price Reference Table

NSE Symbol	AARTIDRUGS
CMP	Rs 427
52-Week High	Rs 657
52-Week Low	Rs 327
Market Cap	Rs 3,660 Cr
P/E	18x
Promoter	50.2%
FII	8.4%
Dividend FY26	Rs 3
Short-Term Target	Rs 517
12M Target	Rs 517-597
Upside	21-40%

Sources: NSE/BSE, Screener.in, publicly available analyst research. April 2026.

Analyst Ratings and Aarti Drugs share price target 2026

Brokerage	Rating	Target	Key View
MOFSL	Buy	Rs 512	FY27 earnings recovery and API Generic Pharma sector leadership
YES Securities	Buy	Rs 520	Quality execution — accumulate at support levels
Kotak Institutional	Add	Rs 491	Monitor Q4 FY26 guidance — maintain position
JM Financial	Neutral	Consensus	Await Q4 FY26 result clarity before adding

Subscribe to Univest Pro for SEBI-registered entry, target and stop-loss on Aarti Drugs.

How to Invest in Aarti Drugs — 5 Steps

Step 1: Research on the Univest Screener

Search AARTIDRUGS on univest.in/screeners. Review quarterly results, FII/DII trend, promoter holding, and analyst consensus on the Aarti Drugs share price target 2026.

Step 2: Identify Entry Level

Aarti Drugs at Rs 427 has key support near Rs 327. Plan entry near support with stop-loss 8-10% below entry. First resistance toward the Aarti Drugs share price target 2026 recovery is Rs 517.

Step 3: Monitor Q4 FY26 Results

Q4 FY26 results (April-May 2026) are the near-term trigger. A beat with positive FY27 guidance triggers re-rating toward 597 — the bull case for the Aarti Drugs share price target 2026.

Step 4: Position Sizing

Allocate maximum 3-5% of your portfolio to any single stock. Never invest more than you can hold for 2+ years through volatility.

Step 5: Track on the Univest App

Download the Univest iOS App or Android App for live price alerts and SEBI-registered research aligned with the Aarti Drugs share price target 2026.

Conclusion — Aarti Drugs share price target 2026

Aarti Drugs (AARTIDRUGS) at Rs 427 offers 21-40% potential upside to the 12-month Aarti Drugs share price target 2026 consensus of Rs 517-597. The bull case to 597 requires FY27 earnings delivery and macro normalisation. The bear case (Rs 327 zone) materialises only on significant earnings disappointment. For long-term investors with a 2-3 year horizon, Aarti Drugs at current levels presents a monitored entry opportunity. For more Aarti Drugs share price target 2026 analysis and peer comparisons, visit Univest Blogs.

Disclaimer: Investment in the share market is subject to market risks. This article is for educational and informational purposes only and does not constitute investment advice. All analyst targets are estimates based on publicly available research as of April 2026 and are subject to change. Verify all data on NSE/BSE before investing. Consult a SEBI-registered financial advisor before making any investment decisions.

Frequently Asked Questions — Aarti Drugs share price target 2026

Q: What is Aarti Drugs share price target for 2026?

The 12-month Aarti Drugs share price target 2026 analyst consensus is Rs 517-597 — implying 21-40% upside from CMP Rs 427. Bull case: 597. Bear case: Rs 327 zone. Track the live Aarti Drugs share price target 2026 on the Univest Screener. These are analyst estimates, not guaranteed returns.

Q: Is Aarti Drugs a good buy at Rs 427?

This article does not constitute investment advice. At Rs 427, Aarti Drugs offers 21-40% upside to the Aarti Drugs share price target 2026 consensus of Rs 517-597. Suitability depends on your risk tolerance and investment horizon. Consult a SEBI-registered financial advisor before investing.

Q: What is Aarti Drugs 52-week high and low?

Aarti Drugs’s 52-week high is Rs 657 and 52-week low is Rs 327. At the current CMP of Rs 427, the stock has corrected from its 52-week high — creating recovery potential for investors aligned with the Aarti Drugs share price target 2026 thesis.

Q: What sector is Aarti Drugs (AARTIDRUGS) in?

Aarti Drugs operates in the API Generic Pharma / Domestic and Export sector. India’s API Generic Pharma sector is growing structurally — driven by rising incomes, government policy, and India’s consumption expansion — underpinning the Aarti Drugs share price target 2026 bull case.

Q: What are the main risks for the Aarti Drugs share price target 2026 thesis?

Key risks: US tariff macro headwinds, valuation at 18x requiring consistent execution, competition in API Generic Pharma, input cost volatility, and FII selling pressure (8.4% holding). Monitor quarterly earnings closely.

Q: What is Aarti Drugs’s market cap?

Aarti Drugs has a market cap of Rs 3,660 Cr as of April 2026. At the Aarti Drugs share price target 2026 of Rs 517-597, the implied market cap would reflect 21-40% appreciation on the current base.

Q: What is Aarti Drugs dividend for FY26?

Aarti Drugs’s FY26 dividend is Rs 3. Track dividend announcements on NSE or the Univest Screener. Dividend yield adds to the total return alongside the Aarti Drugs share price target 2026 capital appreciation potential.

Q: How to buy Aarti Drugs shares?

Buy Aarti Drugs (AARTIDRUGS) through any SEBI-registered broker on NSE. Research first on the Univest Screener, set a price alert at the Rs 327 support zone, and download the Univest App for SEBI-registered research on the Aarti Drugs share price target 2026.